Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic is supported by a differentiated oral immunology platform in which vidofludimus calcium combines DHODH inhibition with Nurr1 activation, creating a dual-mechanism profile that may address both inflammatory activity and neuroprotective repair in RMS and progressive MS while also showing a favorable safety record across 3,500+ patients with no evidence of increased hepatotoxicity, serious infections, cardiovascular risk, GI toxicities, cytopenias, or macular edema. The investment case is further strengthened by clinical validation from the Phase 2 EMPhASIS trial, where RRMS data showed reductions in 3-month and 6-month CDW and OLE follow-up found over 92% of patients remained free of both outcomes after an additional 144 weeks, while over 350 patients remained on treatment in the CALLIPER OLE as of January 2026, suggesting durability and tolerability that could support long-term use in a market where safety is the dominant prescribing attribute. Financially, the modeled opportunity is meaningful because the company’s MS franchise is projected to scale from $800MM in global sales in 2031 to $1.3B in 2035 under the cited assumptions, with a conservative valuation framework still implying substantial upside from current development milestones including the Phase 3 ENSURE topline in late 2026 and the confirmatory Phase 3 program in PPMS later in 2026.

Immunic is viewed negatively because its lead asset and broader pipeline remain highly exposed to clinical and regulatory failure, and the company itself acknowledges risks of being unable to achieve sales estimates, facing manufacturing or shipment disruptions, and suffering commercial pressure from current and future therapies. The investment case is further weakened by the fact that even favorable EMPhASIS safety data must still translate into durable efficacy and uptake against entrenched MS competitors such as Ocrevus, Kesimpta, Aubagio, and Briumvi, while the report explicitly anticipates dilution from common warrant exercises should Phase 3 results prove positive. Although the company has a large theoretical MS opportunity, the base case only assumes 3.5% market penetration and still depends on a 25-35% relapse-risk reduction with no new safety signals, underscoring how much execution, clinical validation, and commercialization risk must break in Immunic’s favor before the business can meaningfully justify value.